Lysophospholipid receptors: signaling and biology.

By I. Ishii, N. Fukushima, X. Ye, J. Chun. Annual Review of Biochemistry, 2004

814 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/16ed4ce3ad9a260c8cff2c85ee4e368f2e918e05

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Susan R. Schwab
2. J. Cyster
3. A. Luster
4. M. Wymann
5. R. Schneiter
6. J. Chun
7. Y. Yung
8. Nicole C. Stoddard

In Physiology

1. M. Wymann
2. R. Schneiter
3. A. Luster

Citations in the corpus

• Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network (2005, background): “The many downstream signals that are generated by ligand occupancy of S1P receptors in several cell types have also been reviewed by other”
• Finding a way out: lymphocyte egress from lymphoid organs (2007, background): “FTY720 has shown promise in phase II clinical trials of multiple sclerosis, and it will be crucial to disentangle the effects on lymphocyte trafficking, the changes in activation of a range of immune cells, and the direct effects on endothelium and neuronal cell types that can also express S1P recep”
• Lipid signalling in disease (2008, background): “Another lipid that is released from cells, lysophosphatidic acid (LPA), also functions in an autocrine and paracrine manner by binding to a family of GPCR”
• The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak (2008, background): “LPA signals through at least five GPCRs designated LPA 1–5 (refs”
• LPA receptor signaling: pharmacology, physiology, and pathophysiology (2014, background): “LPA receptors are found on virtually all immune cell types and organs, including lymphocytes (144), dendritic cells (DCs) (152, 153), thymus, and spleen (20, 77, 154).”
• HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. (2004, background): “lysophosphatidylcholine, although the ligand identities of these receptors is currently ambiguous (44).”
• Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis (2010, background): “Activation of S1P receptor subtypes initiates distinct intracellular signaling pathways that can produce opposing effects.(34,35,56,57) The cellular responses mediated by S1P receptors may thus vary with developmental stage and involved receptor subtypes.”